All In Biotech

Drug Trial Radar · NCT00348309

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.

Last checked: Nov 19, 2026Latest source record: Nov 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,496 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,496

Actual

Start

Jul 6, 2006

Primary completion

Jan 1, 2009

Study completion Jan 28, 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects their response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.

Conditions

  • Alzheimer's Disease

Interventions

  • Rosiglitazone Extended Release 2mgDrug

    Rosiglitazone Extended Release 2mg OD

  • Rosiglitazone Extended Release 8mgDrug

    Rosiglitazone Extended Release 8mg OD

  • PlaceboOther

    Placebo

  • DonepezilOther

    Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48Time frame: Baseline (Week 0) and Week 48
  2. Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4Time frame: Baseline (Week 0) and Week 48

Locations

249 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Litchfield Park, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Rancho Mirage, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Sherman Oaks, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Delray Beach, Florida

  • GSK Investigational Site

    Hallandale, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Hoffman Estates, Illinois

  • GSK Investigational Site

    Fort Wayne, Indiana

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Glen Burnie, Maryland

  • GSK Investigational Site

    Rockville, Maryland

  • GSK Investigational Site

    Saint Paul, Minnesota

  • GSK Investigational Site

    Lebanon, New Hampshire

  • GSK Investigational Site

    Morristown, New Jersey

  • GSK Investigational Site

    Nutley, New Jersey

  • GSK Investigational Site

    Princeton, New Jersey

  • GSK Investigational Site

    Stratford, New Jersey

  • GSK Investigational Site

    Albany, New York

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    South Ogden, Utah

Showing 40 of 249 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.